Table 2.
Treat All with | Treat according to the Model | ||||||||
---|---|---|---|---|---|---|---|---|---|
Placebo (“Treat None”) | Glatiramer Acetate | Dimethyl Fumarate | Natalizumab | Placebo (“Treat None”) | Glatiramer Acetate | Dimethyl Fumarate | Natalizumab | Total | |
Treatment rate | 0% | 100% | 100% | 100% | |||||
Event rate | as a meta-analysis of all placebo arms in | as a meta-analysis of all placebo arms in | |||||||
Decrease in event rate | 0 | ||||||||
Net strategy benefit | 0 |
The threshold values for glatiramer acetate, dimethyl fumarate, and natalizumab are noted as and respectively.